We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pancreatic neuroendocrine tumors: a comprehensive review.
- Authors
Zhou, Chenfei; Zhang, Jun; Zheng, Ying; Zhu, Zhenggang
- Abstract
Pancreatic neuroendocrine tumors (NETs) are a heterogeneous group of tumors. Despite being relatively rare, representing just 1-2% of all pancreatic neoplasms, the incidence of pancreatic NET has increased over the past two decades. Although the primary treatment for localized NET is surgical resection, there is still a lack of effective therapeutic options for patients with advanced unresectable pancreatic NET. Recently, the targeted agents sunitinib malate (SUTENT®, Pfizer Inc, NYC) and everolimus (AFINITOR®, Novartis, Basel, Switzerland)-both with different mechanisms of action-received United States Food and Drug Administration approval for the treatment of progressive, well-differentiated, pancreatic NET in patients with unresectable, locally advanced or metastatic disease. SUTENT® also received approval for this indication by the European Commission in 2010. Our article presents an overview of pancreatic NET, with a focus on their diagnostic work-up, clinical presentation and treatment options. Topics for further investigation of targeted therapy are also discussed.
- Publication
International journal of cancer, 2012, Vol 131, Issue 5, p1013
- ISSN
1097-0215
- Publication type
Journal Article
- DOI
10.1002/ijc.27543